anacetrapib Report issue

Small molecule Experimental
AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW
  • Now
Anacetrapib is a CETP inhibitor which was being developed to treat elevated cholesterol levels in an effort to prevent cardiovascular disease. In 2017 its development was abandoned by Merck.   Wikipedia

Chemistry

  • SMILES: COc1cc(F)c(C(C)C)cc1-c1ccc(C(F)(F)F)cc1CN1C(=O)O[C@H](c2cc(C(F)(F)F)cc(C(F)(F)F)c2)[C@@H]1C
  • InChIKey: MZZLGJHLQGUVPN-HAWMADMCSA-N
  • Mol. Mass: 637.51
  • ALogP: 9.76
  • ChEMBL Molecule:
    anacetrapib  
More Chemistry

Pharmacology

Alternative names

anacetrapib | mk0859 | mk 0859 | mk-0859

Organizations (2)

Research & Development (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (10)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (10)


 

Atherosclerosis (Phase 3)

Blood Pressure (Phase 1)

Dyslipidemias (Phase 3)

Heart Diseases (Phase 3)

Homozygous Familial Hypercholesterolemia (Phase 3)

Hypercholesterolemia (Phase 3)

Hyperlipidemias (Phase 1)

Hyperlipoproteinemia Type II (Phase 3)

Hyperlipoproteinemia Type V (Phase 2)

Risk Factors (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 15
  • # of Trial Organizations: 2

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue